MS Clinical Trials in Kansas
27 active trials · 14 recruiting
27 active multiple sclerosis clinical trials have at least one study site in Kansas, 14 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.
Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 3 MS treatment centers in Kansas; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.
Active MS trials with sites in Kansas
RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Sponsor: TG Therapeutics, Inc.
Ublituximab · Placebo
25 states800 participantsDetails ›
RecruitingPhase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Sponsor: Amgen
Ocrelizumab (US) · Ocrelizumab (EU)
17 states444 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Sponsor: Novartis Pharmaceuticals
Remibrutinib oral treatment · Ocrelizumab
18 states360 participantsDetails ›
RecruitingPhase 1
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Sponsor: National Cancer Institute (NCI)
Biospecimen Collection · Nivolumab
19 states300 participantsDetails ›
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Sponsor: Novartis Pharmaceuticals
Remibrutinib (blinded) · Placebo
10 states1275 participantsDetails ›
RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Sponsor: Celgene
BMS-986368 · Placebo
11 states200 participantsDetails ›
RecruitingPhase 1
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Sponsor: Tr1X, Inc.
TRX319 · Bendamustine
2 states39 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Teriflunomide
35 states1600 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Placebo
38 states900 participantsDetails ›
RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
CC-97540 · Fludarabine
14 states120 participantsDetails ›
RecruitingPhase 2
Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection
Sponsor: University of Kansas Medical Center
Telehealth cognitive behavioral thera… · Web-based cognitive behavioral therap…
1 state90 participantsDetails ›
RecruitingPhase 2
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
Sponsor: University of Kansas Medical Center
Cognitive behavioral therapy for inso… · Sleep and lifestyle education
1 state70 participantsDetails ›
RecruitingNA
Dry Needling in Multiple Sclerosis
Sponsor: University of Kansas Medical Center
Dry needling · Sham dry needling
1 state24 participantsDetails ›
RecruitingNA
User-friendliness of a Portable Driving Simulator
Sponsor: University of Kansas Medical Center
Low-Fidelity PDS · High Fidelity Fixed-Base Simulator
1 state30 participantsDetails ›
Closed to new patientsPhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor: Novartis Pharmaceuticals
Remibrutinib · Teriflunomide
23 states1011 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Fenebrutinib · Ocrelizumab
24 states985 participantsDetails ›
Closed to new patientsPhase 3
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Sponsor: Novartis Pharmaceuticals
Ofatumumab approved dose · Ofatumumab new dose
24 states196 participantsDetails ›
Closed to new patientsPhase 3
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Fenebrutinib · Teriflunomide
13 states751 participantsDetails ›
Closed to new patientsPhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor: Novartis Pharmaceuticals
Remibrutinib · Teriflunomide
27 states1001 participantsDetails ›
Closed to new patientsPhase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Sponsor: Novartis Pharmaceuticals
Ofatumumab · Tetanus toxoid (TT) containing vaccin…
32 states1882 participantsDetails ›
Closed to new patientsPhase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Sponsor: TG Therapeutics, Inc.
Ublituximab
14 states1100 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Ocrelizumab · Placebo
5 states1013 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Ocrelizumab · Ocrelizumab
20 states864 participantsDetails ›
Closed to new patientsPhase 3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sponsor: Sanofi
Tolebrutinib · Placebo
27 states2500 participantsDetails ›
Closed to new patientsPhase 3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Ocrelizumab
26 states1300 participantsDetails ›
Closed to new patientsPhase 4
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
Sponsor: University of Texas Southwestern Medical Center
Cladribine
2 states40 participantsDetails ›
Closed to new patientsNA
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Sponsor: Johns Hopkins University
Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…
28 states900 participantsDetails ›
MS trials in other states
The app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.